EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Outcome Associated With Beta‐Lactam Allergy Labels in Hospitalized Patients in Belgium

Liesbeth Gilissen, Greet Van De Sijpe, Annouschka Laenen, Peter Declercq, Dries Wets, Ileana Ghiordanescu, Anca Mirela Chiriac, Willy E Peetermans, Paul De Munter, Isabel Spriet, Rik Schrijvers iD

Clinical and Translational Allergy · 2026-04 · 16 (4)

DOI: 10.1002/clt2.70166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 27.03.2026. Verfasst von Liesbeth Gilissen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitaire Ziekenhuizen Leuven, KU Leuven, KU Leuven, Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the United States, beta‐lactam allergy labels (BLAL) are documented in 9%–16% of hospitalized patients and associated with worse clinical outcomes such as increased mortality, length of hospital stay (LOS), intensive care unit (ICU) admission, and use of alternative antibiotics, providing an incentive for broad delabeling protocols. In Europe, BLAL prevalences are lower (0.6%–5%) and the association with clinical outcomes insufficiently explored. Therefore, we assessed the association between BLAL and penicillin allergy label (PenAL) and clinical outcomes and antibiotic use in hospitalized patients in Belgium.

Methods

Retrospective population‐based cohort study of all patients admitted to the University Hospitals Leuven between 2010 and 2018 for pneumonia, pyelonephritis (therapeutic indications), or appendectomy, coronary artery bypass grafting, total knee or hip replacement (prophylactic indications) or heart, kidney, liver, or lung transplantation (mixed indications). Multivariable regression analysis was performed, using BLAL or PenAL as independent variable, and age, gender, Charlson Comorbidity Index, and diagnosis as a priori hypothesized confounders.

Results

We included 21,999 patients accounting for 23,842 admissions. A BLAL was recorded in 1394 (6.3%) patients, with 1113 (5.1%) having an unspecified PenAL. An increased use of next‐line antibiotics was observed among patients with BLAL or PenAL. However, BLAL or PenAL were not associated with altered in‐hospital or 3‐month post‐hospitalization mortality, LOS or ICU admission.

Conclusion

Despite altered antibiotic use, we observed no association of BLAL or PenAL with clinical outcome parameters, highlighting regional differences and limiting transferability of non‐EU findings to guide EU delabeling protocols.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial stewardshipbeta‐lactamsdelabelingdrug allergypenicillin allergy

Autor:innen und Institutionen

  • Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.
  • Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
  • Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
  • KU Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), Leuven, Belgium.
  • Department of General Internal Medicine, Allergy and Clinical Immunology Unit, University Hospitals Leuven, Leuven, Belgium.
  • Laboratoire Inserm UMR1327 ISCHEMIA, Tours, France.

ORCID-Profile: Rik Schrijvers

Förderung

  • Universitaire Ziekenhuizen Leuven, KU Leuven
  • KU Leuven
  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Gilissen, L., Sijpe, G. V., Laenen, A., Declercq, P., Wets, D., Ghiordanescu, I., Chiriac, A. M., Peetermans, W. E., Munter, P., Spriet, I., & Schrijvers, R. (2026). Clinical Outcome Associated With Beta‐Lactam Allergy Labels in Hospitalized Patients in Belgium. Clinical and Translational Allergy, 16(4). https://doi.org/10.1002/clt2.70166

Vancouver

Gilissen L, Sijpe GV, Laenen A, Declercq P, Wets D, Ghiordanescu I, et al. Clinical Outcome Associated With Beta‐Lactam Allergy Labels in Hospitalized Patients in Belgium. Clinical and Translational Allergy. 2026;16(4). doi:10.1002/clt2.70166

BibTeX
@article{Gilissen2026,
  author = {Gilissen, Liesbeth and Sijpe, Greet Van De and Laenen, Annouschka and Declercq, Peter and Wets, Dries and Ghiordanescu, Ileana and Chiriac, Anca Mirela and Peetermans, Willy E and Munter, Paul De and Spriet, Isabel and Schrijvers, Rik},
  title = {Clinical Outcome Associated With Beta‐Lactam Allergy Labels in Hospitalized Patients in Belgium},
  journal = {Clinical and Translational Allergy},
  year = {2026},
  volume = {16},
  number = {4},
  doi = {10.1002/clt2.70166}
}
Kostenlos starten →